Form 4 holding
Chief Financial Officer
CRISPR Therapeutics AG
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 18,000
- Estimated value
- Report date
- 26 Oct 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount